A randomized, double-blind, placebo-controlled, single ascending dose study exploring the preliminary safety, tolerability and pharmacokinetics of GSK1223249 administered by intravenous (IV) infusion to patients with relapsing forms of multiple sclerosis, not on disease modifying therapy.

Trial Profile

A randomized, double-blind, placebo-controlled, single ascending dose study exploring the preliminary safety, tolerability and pharmacokinetics of GSK1223249 administered by intravenous (IV) infusion to patients with relapsing forms of multiple sclerosis, not on disease modifying therapy.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Ozanezumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2017 Last checked against ClinicalTrials.gov record.
    • 11 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 26 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top